Last €70.45 EUR
Change Today -0.128 / -0.18%
Volume 121.0
VX1 On Other Exchanges
As of 5:28 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VX1) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/14 - €74.89
52 Week Low
11/13/13 - €44.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

vertex pharmaceuticals inc (VX1) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VX1) Details

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. It markets KALYDECO in the United States and European Union as a treatment for the patients with cystic fibrosis six years of age and older who have the G551D mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company also provides INCIVEK in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus infection, as well as markets telaprevir in other international markets. It also develops Ivacaftor in combination with CFTR corrector compounds, which is in Phase III development program; and evaluates VX-661, a second investigational CFTR corrector, in combination with ivacaftor, in Phase II clinical development. The company identifies and develops next-generation CFTR corrector compounds that evaluate in regimens combining ivacaftor with two CFTR corrector compounds. It is involved in various other research and early-stage development programs, including programs in the areas of oncology, multiple sclerosis, and other serious and rare diseases. Vertex Pharmaceuticals Incorporated has collaboration agreements with Janssen Pharmaceutica NV and Mitsubishi Tanabe Pharma Corporation. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Founded in 1989

vertex pharmaceuticals inc (VX1) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $583.0K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $619.8K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $553.8K
Chief Legal Officer and Executive Vice Presid...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2013.

vertex pharmaceuticals inc (VX1) Key Developments

Vertex Pharmaceuticals Inc. Stops Selling Incivex, Hepatitis C Drug

Vertex Pharmaceuticals Inc. has told doctors it will discontinue sales of Incivek, the hepatitis C treatment that was the first drug developed by the Boston Company. Incivek was approved by US and European regulators in 2011. More than 100,000 people globally have taken it over the past three years. But new and better treatments for hepatitis C especially the hugely successful pill Sovaldi has virtually wiped out sales of Incivek. The move was the latest in a series of steps Vertex has taken over the past year to back away from the hepatitis C market and refocus the company's efforts on treatments for cystic fibrosis, a life-threatening genetic disease that affects the lungs and digestive system.

Vertex Receives European Approval for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations

Vertex Pharmaceuticals Incorporated announced that the European Commission has approved KALYDECO(TM) (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Today's approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2014. KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have the G551D mutation, which is the most common gating mutation. The eight additional gating mutations included in today's approval are: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. In Europe, approximately 250 people ages 6 and older have one of these non-G551D gating mutations.

Vertex Announces Phase 2 Results of Combination Treatment in People with One Copy of F508del CF Mutation

Vertex Pharmaceuticals Inc. announced results from a Phase 2 clinical trial of the cystic fibrosis drug ivacaftor (Kalydeco.,) in combination with another potential therapy, lumacaftor, in people with one copy of the F508del mutation, ages 18 and older. In the study, those who received the two drugs in combination did not demonstrate a significant improvement in lung function, a primary endpoint of the 8-week trial. Both ivacaftor and lumacaftor are aimed at treating the underlying cause of CF - a defective protein, called CFTR, caused by mutations in the CF gene.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VX1:GR €70.45 EUR -0.128

VX1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VX1.
View Industry Companies

Industry Analysis


Industry Average

Valuation VX1 Industry Range
No financial data is available for VX1.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at